Kurume University Cancer Vaccine Trial Termination Announcement
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Official Trial Closure Notice
- November 7, 2019
Kurume University announced official termination of peptide cancer vaccine clinical trial program, effective January 31, 2020.
Trial Background
Kurume University's personalized peptide cancer vaccine program attracted significant patient enrollment, particularly from Taiwan. Phase II trial enrolled treatment-experienced patients with continued enrollment until July 2019.
Clinical Trial Outcomes
Phase III trials in two cancer types demonstrated:
- Prostate Cancer Phase III: Failed to meet primary overall survival extension endpoint
- Glioblastoma Phase III: Failed to meet primary overall survival extension endpoint
Based on these negative efficacy results and regulatory requirements under new clinical research law, the Cancer Vaccine Center Steering Committee and independent safety monitoring committee recommended trial termination.
Regulatory Status
Trial termination due to:
- Failure to demonstrate survival benefit
- Non-compliance with new Clinical Research Law (effective April 2020)
Final Treatment Date
January 31, 2020 represents final date for vaccine administration.
Continuing patients previously enrolled may transition to alternative protocols as clinically appropriate.
Trial Leadership
Center Director: Shigeru Yuya, MD, Kurume University Cancer Vaccine Center Announcement Date: October 28, 2019
Clinical Conclusions
Although peptide vaccine approach demonstrated theoretical promise, Phase III efficacy data did not support continued clinical development in prostate cancer or glioblastoma populations.
Data Source
Kurume University Cancer Vaccine Center Official Notice
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4